How Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Advancing Sonelokimab Toward U.S. Approval and Beyond?

Sonal Goyal

05 November 2026 12:37 PM AEDT

How Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Advancing Sonelokimab Toward U.S. Approval and Beyond?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• MoonLake submitted a Biologics License Application to the FDA for sonelokimab in moderate-to-severe hidradenitis suppurativa in adults and adolescents

• Phase 3 IZAR-1 trial in psoriatic arthritis met all clinical endpoints at Week 16 for sonelokimab 60 mg with induction, showing a 42.1% ACR50 response rate

• Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with topline results expected in Q1 2027

• MoonLake ended Q3 2026 with $498.5 million in cash and equivalents, with an expected runway to mid-2028

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biotechnology company focused on next-level therapies for inflammatory diseases, provided a Business update and reported third-quarter 2026 financial results. The quarter was marked by the submission of a Biologics License Application (BLA) to the FDA and positive clinical trial readouts across multiple indications for its lead candidate, sonelokimab.

BLA Submission for Hidradenitis Suppurativa

On September 30, 2026, MoonLake submitted a BLA to the U.S. Food and Drug Administration seeking approval of sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients aged 12 years and older. The company expects to receive notification from the FDA regarding whether the BLA submission is accepted for review within approximately 60 days of submission, with the planned review timeline expected within approximately 74 days.

The BLA is supported by data from the MIRA and VELA clinical programs, including VELA-TEEN, which MoonLake expects to complete in the fourth quarter of 2026. Final results from VELA-TEEN are planned for submission at a scientific conference in Q1 2027. The company is also advancing its preparations for a potential U.S. commercial launch of sonelokimab, including market access, medical affairs, patient engagement, and commercial infrastructure activities.

Phase 3 Progress in Psoriatic Arthritis

In August 2026, MoonLake reported positive Week 16 primary endpoint results from the Phase 3 IZAR-1 trial in psoriatic arthritis (PsA). The study met all clinical endpoints for sonelokimab 60 mg with induction, with 42.1% of biologic-naive patients achieving an American College of Rheumatology 50 (ACR50) response at Week 16. The data showed clinically meaningful improvements across patient-reported and physical outcomes and demonstrated efficacy across multiple PsA disease domains.

Consistent with the unblinding protocol defined with the FDA, the Week 16 topline disclosure included absolute response levels and endpoint outcomes only for the sonelokimab 60 mg with induction arm. Comparative analyses versus placebo and detailed treatment arm data remain blinded until the trial is completed.

In September 2026, MoonLake completed enrollment for the Phase 3 IZAR-2 trial in PsA. Initial topline results following a predefined unblinding protocol are expected in Q1 2027. Additionally, the company expects results from the P-OLARIS trial to become available in early 2027.

Expanding the Indication Pipeline

MoonLake reported that enrollment in the Phase 3 NOVA trial in palmoplantar pustulosis is on track to commence in November 2026, adding another inflammatory disease indication to the sonelokimab development program.

Financial Position

As of September 30, 2026, MoonLake held $498.5 million in cash, cash equivalents, and short-term marketable Debt securities. The company expects its current cash runway to extend to mid-2028. Additionally, up to $400 million in non-dilutive Capital remains available through a debt Facility with Hercules Capital, providing further financial flexibility as the company approaches potential commercialization.

What It All Means

MoonLake's Q3 2026 business update reflects a company transitioning from clinical-stage development toward potential commercialization of sonelokimab. The BLA submission for HS represents the most advanced regulatory milestone for the program, while the Phase 3 PsA data and upcoming NOVA trial enrollment extend the candidate's reach into additional inflammatory disease indications. With nearly $500 million in available cash and access to additional non-dilutive funding, MoonLake appears positioned to fund its development and pre-launch activities through the anticipated regulatory review period.

FAQs

Q: When did MoonLake submit its BLA for sonelokimab?

A: MoonLake submitted its BLA to the FDA on September 30, 2026, seeking approval for sonelokimab in moderate-to-severe hidradenitis suppurativa.

Q: What were the Phase 3 IZAR-1 trial results for psoriatic arthritis?

A: The trial met all clinical endpoints at Week 16, with 42.1% of biologic-naive patients treated with sonelokimab 60 mg with induction achieving an ACR50 response.

Q: How much cash does MoonLake have on hand?

A: As of September 30, 2026, MoonLake held $498.5 million in cash, cash equivalents, and short-term marketable debt securities, with an expected runway to mid-2028.

Q: What additional indications is MoonLake pursuing for sonelokimab?

A: Beyond HS and psoriatic arthritis, MoonLake is preparing to begin enrollment in the Phase 3 NOVA trial in palmoplantar pustulosis in November 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.